Literature DB >> 12965921

Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients.

Justin Digby1, John Kalbfleisch, Andy Glenn, Angie Larsen, William Browder, David Williams.   

Abstract

Fungal infections in the critically ill patient are difficult to diagnose and are associated with a high mortality rate. A major obstacle to managing fungal infection is the lack of a reliable clinical assay that will rapidly identify patients with fungal sepsis. Glucans are polymers of glucose that are found in the cell wall of fungi and certain bacteria. Glucans are also released from the fungal cell wall into the extracellular milieu. Several studies have reported that detection of fungal glucan in serum or plasma is useful in the diagnosis of mycoses. However, recent studies have questioned the clinical utility of this assay. In this study, we examined serum glucan levels in intensive care unit (ICU) patients and attempt to correlate serum glucan levels with the presence of fungal infection. Following attainment of informed consent, serum was harvested from 46 ICU patients with confirmed fungal infections, confirmed bacterial infections, or no evidence of infection. Sera from eight healthy volunteers served as control. Serum glucan was assayed with a glucan-specific Limulus assay. Serum glucan levels were increased (69.6 +/- 17 pg/ml; P < 0.001) in ICU patients versus the normal (11.5 +/- 1.3 pg/ml) and noninfected ICU (27.4 +/- 17 pg/ml) controls. However, serum glucan levels were not different in patients with confirmed fungal infections versus those with confirmed bacterial infections. Thus, serum glucan levels did not show a correlation with the presence of fungal infections and do not appear to be specific for fungal infections. However, the assay may be useful as a negative predictor of infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12965921      PMCID: PMC193887          DOI: 10.1128/cdli.10.5.882-885.2003

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  12 in total

1.  Evaluation of a new laboratory test measuring plasma (1-->3)-beta-D-glucan in the diagnosis of Candida deep mycosis: comparison with a serologic test.

Authors:  M Hiyoshi; S Tagawa; S Hashimoto; C Sakamoto; N Tatsumi
Journal:  Kansenshogaku Zasshi       Date:  1999-01

Review 2.  Opportunistic fungal infections in the critically ill.

Authors:  B K Shelton
Journal:  Crit Care Nurs Clin North Am       Date:  2000-09       Impact factor: 1.326

Review 3.  Diagnosis of fungal infections: current status.

Authors:  David A Stevens
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

4.  Detection of plasma (1 --> 3)-beta-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremonium fungaemias.

Authors:  M Yoshida; T Obayashi; A Iwama; M Ito; S Tsunoda; T Suzuki; K Muroi; M Ohta; S Sakamoto; Y Miura
Journal:  J Med Vet Mycol       Date:  1997 Sep-Oct

5.  Evaluation of plasma (1-->3)-beta-D-glucan measurement by the kinetic turbidimetric Limulus test, for the clinical diagnosis of mycotic infections.

Authors:  T Mori; H Ikemoto; M Matsumura; M Yoshida; K Inada; S Endo; A Ito; S Watanabe; H Yamaguchi; M Mitsuya; M Kodama; T Tani; T Yokota; T Kobayashi; J Kambayashi; T Nakamura; T Masaoka; H Teshima; T Yoshinaga; S Kohno; K Hara; S Miyazaki
Journal:  Eur J Clin Chem Clin Biochem       Date:  1997-07

6.  An evaluation of serodiagnostic tests in patients with candidemia: beta-glucan, mannan, candida antigen by Cand-Tec and D-arabinitol.

Authors:  S Kohno; K Mitsutake; S Maesaki; A Yasuoka; T Miyazaki; M Kaku; H Koga; K Hara
Journal:  Microbiol Immunol       Date:  1993       Impact factor: 1.955

7.  Improved survival from fungaemia in patients with haematological malignancies: analysis of risk factors for death and usefulness of early antifungal therapy.

Authors:  A Iwama; M Yoshida; A Miwa; T Obayashi; S Sakamoto; Y Miura
Journal:  Eur J Haematol       Date:  1993-09       Impact factor: 2.997

8.  Relationship between conformation and biological response for (1----3)-beta-D-glucans in the activation of coagulation factor G from limulus amebocyte lysate and host-mediated antitumor activity. Demonstration of single-helix conformation as a stimulant.

Authors:  H Saitô; Y Yoshioka; N Uehara; J Aketagawa; S Tanaka; Y Shibata
Journal:  Carbohydr Res       Date:  1991-09-18       Impact factor: 2.104

9.  Plasma (1-->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes.

Authors:  T Obayashi; M Yoshida; T Mori; H Goto; A Yasuoka; H Iwasaki; H Teshima; S Kohno; A Horiuchi; A Ito
Journal:  Lancet       Date:  1995-01-07       Impact factor: 79.321

10.  Receptor binding and internalization of a water-soluble (1-->3)-beta-D-glucan biologic response modifier in two monocyte/macrophage cell lines.

Authors:  A Müller; P J Rice; H E Ensley; P S Coogan; J H Kalbfleish; J L Kelley; E J Love; C A Portera; T Ha; I W Browder; D L Williams
Journal:  J Immunol       Date:  1996-05-01       Impact factor: 5.422

View more
  43 in total

1.  Prospective survey of (1→3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting.

Authors:  John F Mohr; Charles Sims; Victor Paetznick; Jose Rodriguez; Malcolm A Finkelman; John H Rex; Luis Ostrosky-Zeichner
Journal:  J Clin Microbiol       Date:  2010-11-03       Impact factor: 5.948

2.  Invasive aspergillosis in the ICU: an emerging disease.

Authors:  Wouter Meersseman; Eric Van Wijngaerden
Journal:  Intensive Care Med       Date:  2007-07-24       Impact factor: 17.440

3.  Beta-D-glucan detection as a diagnostic test for invasive aspergillosis in immunocompromised critically ill patients with symptoms of respiratory infection: an autopsy-based study.

Authors:  Greet De Vlieger; Katrien Lagrou; Johan Maertens; Eric Verbeken; Wouter Meersseman; Eric Van Wijngaerden
Journal:  J Clin Microbiol       Date:  2011-08-31       Impact factor: 5.948

4.  Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1,3)-β-D-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease.

Authors:  J Acosta; M Catalan; A del Palacio-Pérez-Medel; J-C Montejo; J De-La-Cruz-Bértolo; M-D Moragues; J Pontón; M A Finkelman; A del Palacio
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-08-03       Impact factor: 3.267

Review 5.  Invasive candidiasis in critical care setting, updated recommendations from "Invasive Fungal Infections-Clinical Forum", Iran.

Authors:  Ashraf Elhoufi; Arezoo Ahmadi; Amir Mohammad Hashem Asnaashari; Mohammad Ali Davarpanah; Behrooz Farzanegan Bidgoli; Omid Moradi Moghaddam; Mohammad Torabi-Nami; Saeed Abbasi; Malak El-Sobky; Ali Ghaziani; Mohammad Hossein Jarrahzadeh; Reza Shahrami; Farzad Shirazian; Farhad Soltani; Homeira Yazdinejad; Farid Zand
Journal:  World J Crit Care Med       Date:  2014-11-04

6.  Nonculture diagnostic methods for invasive fungal infections.

Authors:  L Joseph Wheat
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

7.  Leukocyte Dectin-1 expression is differentially regulated in fungal versus polymicrobial sepsis.

Authors:  Tammy R Ozment-Skelton; Elizabeth A deFluiter; Tuanzhu Ha; Chuanfu Li; Bridget M Graves; Donald A Ferguson; John B Schweitzer; Johanna Preizsner; Gordon D Brown; Siamon Gordon; John H Kalbfleisch; David L Williams
Journal:  Crit Care Med       Date:  2009-03       Impact factor: 7.598

8.  Improved detection of circulating Aspergillus antigen by use of a modified pretreatment procedure.

Authors:  Monique A S H Mennink-Kersten; Dorien Ruegebrink; Rocus R Klont; Adilia Warris; Nicole M A Blijlevens; J Peter Donnelly; Paul E Verweij
Journal:  J Clin Microbiol       Date:  2008-02-20       Impact factor: 5.948

9.  Levels of (1→3)-β-D-glucan, Candida mannan and Candida DNA in serum samples of pediatric cancer patients colonized with Candida species.

Authors:  Eiman Mokaddas; Mona H A Burhamah; Zia U Khan; Suhail Ahmad
Journal:  BMC Infect Dis       Date:  2010-10-06       Impact factor: 3.090

Review 10.  Management of invasive aspergillosis in patients with COPD: rational use of voriconazole.

Authors:  Florence Ader; Anne-Lise Bienvenu; Blandine Rammaert; Saad Nseir
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.